56.74

1.53% -0.88

After Hours: 56.74

Kiniksa Pharmaceuticals International Plc (KNSA)

Overview News Price History Option Chain Financials Discussions Forecast

Kiniksa Pharmaceuticals International Plc stock is traded at $56.74, with a volume of 618.72K. It is down -1.53% in the last 24 hours and up +16.22% over the past month. Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

Previous Close:

$57.62

Open:

$57.415

24h Volume:

618.72K

Relative Volume:

0.88

Market Cap:

$4.37B

Revenue:

$754.05M

Net Income/Loss:

$73.06M

P/E Ratio:

62.54

EPS:

0.9073

Net Cash Flow:

$164.23M

1W Performance:

+5.37%

1M Performance:

+16.22%

6M Performance:

+44.97%

1Y Performance:

+104.25%

1-Day Range:

$56.09

$58.20

1-Week Range:

$52.29

$58.20

52-Week Range:

$24.85

$58.20

Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile

Name

Kiniksa Pharmaceuticals International Plc

Sector

Healthcare (1106)

Industry

Drug Manufacturers - Specialty & Generic (84)

Phone

(781) 431-9100

Address

105 PICCADILLY, SECOND FLOOR, LONDON

Employee

366

Twitter

@kiniksa

Next Earnings Date

2026-04-28

Latest SEC Filings

KNSA's Discussions on Twitter

Compare KNSA vs TAK, ZTS, TEVA, HLN, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KNSA Kiniksa Pharmaceuticals International Plc	56.74	4.43B	754.05M	73.06M	164.23M	0.9073
TAK Takeda Pharmaceutical Co Adr	16.55	52.32B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	112.54	47.38B	9.47B	2.67B	2.28B	6.0218
TEVA Teva Pharmaceutical Industries Ltd Adr	35.86	41.16B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.17	41.02B	14.54B	2.22B	2.58B	0.4871
UTHR United Therapeutics Corp	572.20	24.67B	3.18B	1.33B	1.04B	27.90

Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-19-26	Initiated	Canaccord Genuity	Buy
Sep-29-25	Initiated	TD Cowen	Buy
Mar-13-25	Initiated	Citigroup	Buy
Sep-13-24	Initiated	Jefferies	Buy
May-03-24	Initiated	Wells Fargo	Overweight
Jun-29-20	Reiterated	BofA Securities	Buy
Apr-01-20	Initiated	BofA/Merrill	Buy
Mar-11-19	Initiated	Barclays	Overweight
Dec-12-18	Reiterated	Wedbush	Outperform
Jun-19-18	Initiated	JMP Securities	Mkt Outperform

View All

Kiniksa Pharmaceuticals International Plc Stock (KNSA) Latest News

May 05, 2026

Why Kiniksa Pharmaceuticals (KNSA) Is Up 5.4% After Raising 2026 Revenue Guidance And What's Next - simplywall.st

May 05, 2026

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Insider John Paolini Sells 58,424 Shares - MarketBeat

May 05, 2026

Kiniksa (NASDAQ: KNSA) CMO sells shares after exercising 58,424 options - Stock Titan

May 05, 2026

Why Kiniksa Pharmaceuticals International stock raced nearly 24% higher today - MSN

May 05, 2026

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 52-Week High on Analyst Upgrade - MarketBeat

May 05, 2026

May 04, 2026

Kornitzer Capital Management Inc. KS Purchases New Shares in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat

May 04, 2026

May 02, 2026

Kiniksa Pharmaceuticals International plc Files 8-K: Announces Consulting Agreement Details and Company Information (April 30, 2026) - Minichart

May 02, 2026

May 01, 2026

Kiniksa hits 52-week high as Regeneron-partnered lead product drives Q1 beat - MSN

May 01, 2026

Kiniksa Pharmaceuticals International (KNSA) Is Up 29.2% After Raising 2026 Net Product Revenue Guidance - Yahoo Finance

May 01, 2026

Sanj Patel Sells 48,565 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock - MarketBeat

May 01, 2026

Kiniksa Pharmaceuticals CSO Resigns and Shifts to Advisor - TipRanks

May 01, 2026

Kiniksa Pharmaceuticals (KNSA) insider sale notice lists 58,424 shares - Stock Titan

May 01, 2026

Kiniksa (NASDAQ: KNSA) CSO Tessari resigns, signs $450/hour consulting deal - Stock Titan

May 01, 2026

Kiniksa (NASDAQ: KNSA) CEO Sanj K. Patel exercises options, sells 48,565 shares under 10b5-1 plan - Stock Titan

May 01, 2026

KNSA SEC FilingsKiniksa Pharmaceuticals International, plc 10-K, 10-Q, 8-K Forms - Stock Titan

May 01, 2026

Kiniksa Pharmaceuticals International (KNSA) Announces Q1 2026 Financial Results - Insider Monkey

May 01, 2026

Apr 30, 2026

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sells $1,217,601.44 in Stock - MarketBeat

Apr 30, 2026

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sells $115,635.41 in Stock - MarketBeat

Apr 30, 2026

Sanj Patel Sells 483,654 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock - MarketBeat

Apr 30, 2026

Kiniksa (NASDAQ: KNSA) CEO’s plan-based option exercises and 508K share sales detailed - Stock Titan

Apr 30, 2026

Pictet Asset Management Holding SA Has $32.49 Million Stake in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat

Apr 30, 2026

Apr 29, 2026

KNSA Maintained by Citigroup -- Price Target Raised to $60 - GuruFocus

Apr 29, 2026

KNSA Maintained by Canaccord Genuity -- Price Target Raised to $64 - GuruFocus

Apr 29, 2026

Kiniksa Pharmaceuticals International Insider Sold Shares Worth $656,260, According to a Recent SEC Filing - marketscreener.com

Apr 29, 2026

Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Director Sells 13,099 Shares of Stock - MarketBeat

Apr 29, 2026

Kiniksa (KNSA) director Quart exercises options, sells 13,099 shares under 10b5-1 plan - Stock Titan

Apr 29, 2026

KNSA Maintained by Wedbush -- Price Target Raised to $59.00 - GuruFocus

Apr 29, 2026